The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

Slides:

Advertisements

Similar presentations

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Advertisements

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

New Horizons for SMA.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

Applying Biosimilars in Hematologic Cancers

T-Cell Exhaustion: Can We Overcome It in Cancer?

Relapsed/Refractory Follicular Lymphoma Conundrums

BRCA, HRR Deficiency, and PARP Inhibitors

Progression After Cancer Immunotherapy in Advanced NSCLC

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Atopic Dermatitis Treatment Landscape

Mid-Year Hemophilia Update

Moving Evidence into Practice: Breast Cancer Highlights From Chicago

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

PARP Inhibitors and Cancer: What Do You Need to Know?

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Managing gBRCA-Positive Metastatic Breast Cancer

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Advancing Care Across the Spectrum of Pancreatic Cancer

PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Parkinson Disease Psychosis

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

PARP Inhibitors.

Locally Advanced Lung Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Molecular Testing in Ovarian Cancer: Is the Time Now?

Patient Questions and Expert Answers in Psoriasis:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Clinical Focus.

Immune Checkpoint Inhibitors in Lung Cancer

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

PARP and PARP Inhibition

PARP Inhibitors Studied in Breast Cancer

BROCADE 2: Study Design

BROCADE 2: Results

I-SPY2: Veliparib/Carboplatin Graduates

BrighTNess: TNBC and Continuous Dosing

BrighTNess Efficacy Data

Phase 2 Studies of Olaparib in gBRCA+ MBC

ABRAZO: Talazoparib Phase 2 in gBRCA+ MBC

OlympiAD Study Design

Primary Endpoint: PFS by BICR

Time to Second Progression or Death (PFS2) by Investigator Assessment

OS: Interim Analysis (46% Data Maturity)

Objective Response by BICR

ORRs in Subgroups

OlympiA Study Population

OlympiA: Methodology

Pilot Study of Neoadjuvant Talazoparib For Early-Stage BRCA+ Breast Cancer

Pilot Study of Neoadjuvant Talazoparib For Early-Stage BRCA+ Breast Cancer (cont)

OlympiAD: AEs

OlympiAD: AEs (cont)

Ongoing Questions

Assays for “BRCAness”/HRD

Mechanisms of Resistance to PARP Inhibitors

Abbreviations

Abbreviations (cont)

Abbreviations (cont)